Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Misfolded protein aggregates disrupt 26S proteasome function, leading to impaired protein homeostasis and neurodegeneration.
• Enhancing 26S proteasome activity through phosphorylation has shown promise in reducing protein aggregates in disease models.

Purpose of the Study:

• To explore novel therapeutic strategies for neurodegenerative diseases by targeting the 26S proteasome.
• To investigate the potential of phosphodiesterase (PDE) inhibitors and G protein-coupled receptor (GPCR)-targeted drugs for modulating proteasome function.

Main Methods:

• Review of existing literature on proteasome function, neurodegeneration pathogenesis, and drug targets.
• Discussion of second messenger signal transduction pathways (cAMP/cGMP) relevant to proteasome activity.
• Exploration of potential therapeutic applications of PDE inhibitors and GPCR-targeted drugs.

Main Results:

• Strategies enhancing 26S proteasome function, such as phosphorylation, can reduce protein aggregates in preclinical models.
• PDE inhibitors and GPCR-targeted drugs offer potential for modulating second messenger signaling.
• These drug classes may allow for region-, cell-, or compartment-specific modulation of proteasome activity.

Conclusions:

• Proteasome activators targeting secondary messengers represent a promising novel therapeutic approach for neurodegenerative diseases.
• Exploiting existing drugs targeting cAMP/cGMP signaling could accelerate the development of treatments.
• Targeting the 26S proteasome via second messenger pathways offers a potential strategy for disease prevention and treatment.